Albumin (human) is under clinical development by Grifols and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Albumin (human)’s likelihood of approval (LoA) and phase transition for Hepatic Encephalopathy took place on 30 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Albumin (human) Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Albumin (human) overview

Human Albumin (Albutein, Plasbumin, albuplan ) is obtained by fractionation of blood plasma. It is formulated as solution for intravenous route of administration. Albutein is indicated for the treatment of hypoalbuminemia, restoration and maintenance of circulating blood volume where it is shown a deficit of volume and use of a colloid is appropriate. Plasbumin is indicated for the treatment of adult respiratory distress syndrome, burns, hypovolemic shock, liver failure. Albutein was under development for kidney transplant.

It is under development for the treatment of amyotrophic lateral sclerosis, Alzheimer's disease, decompensated acute-on-chronic liver cirrhosis, hepatic encephalopathy, septic shock, uncomplicated ascites.

Grifols overview

Grifols is a pharmaceutical and chemical manufacturing company engaged on enhancing the health and well-being of patients worldwide. It is focused on research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. It produces plasma derived protein therapies for patients suffering with rare, chronic and life-threatening infections. Grifols offers biological materials for clinical trials, biotechnology research, manufacturing pharmaceutical and diagnostic products. Grifols provides transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. The company offers its products to hospitals, pharmacies and healthcare professionals. It offers products in the US, Canada, Europe, and Rest of the world. Grifols is headquartered in Barcelona, Spain.

Quick View Albumin (human) LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Albumin (human)
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Dermatology
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Hematological Disorders
  • Immunology
  • Metabolic Disorders
  • Respiratory
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.